South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

donmed -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

donmed -

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate 25 mg in 1 ml - fluphenazine decanoate injection, usp is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). fluphenazine decanoate injection, usp has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate 25 mg in 1 ml - fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). fluphenazine decanoate injection has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate injection is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.

United States - English - NLM (National Library of Medicine)

eugia us llc - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate 125 mg in 5 ml - fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). fluphenazine decanoate injection has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate injection is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may oc

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - ubidecarenone - orange-yellow tablet, diameter: 6.0 mm, thickness: 2.5 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - ubidecarenone - yellow to orange-yellow tablet, diameter: 5.5 mm, thickness: 2.9 mm

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rwr veterinary products pty ltd - nandrolone decanoate - parenteral liquid/solution/suspension - nandrolone decanoate steroid-anabolic active 50.0 mg/ml - endocrine system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic